Individual comparative studies suggest that nabumetone has a gastrointestinal (GI) safety
profile superior to comparator NSAIDs but lack power to show a statistical difference. The
aim of this study was to evaluate systematically the difference in GI adverse events—
especially the rate of perforations, ulcers, and bleeds (PUBs)—between studies, meta-
analyses of comparative trials of nabumetone and conventional NSAIDs, and postmarketing,
open-label studies of nabumetone meeting predefined inclusion and exclusion criteria. A …